TITLE

Tainted weight-loss products

AUTHOR(S)
Kondro, Wayne
PUB. DATE
April 2009
SOURCE
CMAJ: Canadian Medical Association Journal;4/28/2009, Vol. 180 Issue 9, p917
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has expanded its list of tainted, over-the-counter weight-loss products, totaling to 72 products. These weight-loss products contain undeclared and unapproved active ingredients that have negative effects on health. Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said the public does not know that these products contain dangerous drugs that could cause serious consequences to their health.
ACCESSION #
38217627

 

Related Articles

  • Costs and Compliance Dominate Agenda for 2011. Wechsler, Jill // Pharmaceutical Technology;Jan2011, Vol. 35 Issue 1, p26 

    The article offers information on the programs of the U.S. Food and Drug Administration (FDA) for pharmaceutical manufacturers. It states that the Prescription Drug User Fee Act (PDUFA) needs to be reauthorized by October 1, 2012 for FDA to proceed collecting around 700 million dollars payment....

  • Generic Drugs Making Waves. Henderson, Lisa // Applied Clinical Trials;Nov2012, Vol. 21 Issue 11, p12 

    The article offers information about the market of generic drugs in the U.S. It informs that the U.S. Food and Drug association (FDA) has ordered generic drug maker industry to report direct to Janet Woodcock, director of Center for Drug Evaluation and Research (CDER). It highlights that the...

  • Zone in on: Regulation. Greb, Erik // Pharmaceutical Technology;Nov2009, Vol. 33 Issue 11, p22 

    The article reports on the new draft guidance released by the U.S. Food and Drug Administration (FDA) for the pharmaceutical industry on Risk Evaluation and Mitigation Strategies (REMS). It states that the proposed REMS include documents, assessments, and modifications of REMS. It notes that...

  • Safety versus Speed in Drug Development. Wechsler, Jill // Pharmaceutical Technology;Nov2009, Vol. 33 Issue 11, p30 

    The article reports on the increased focus in post approval drug-safety monitoring by the U.S Food and Drug Administration (FDA) that raises concerns about delays in approving new drugs for market. It states that director Janet Woodcock at the Center for Drug Evaluation and Research (CDER) has...

  • Drug Regulators Mark First Anniversary of FDAAA. Young, Donna // BioWorld Today;9/30/2008, Vol. 19 Issue 190, p1 

    The article highlights the first anniversary of the FDA Amendments Act (FDAAA), which gave the U.S. Food and Drug Administration (FDA) the ability to require, rather than negotiate, safety labeling changes in drugs. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research,...

  • FDA Revamps to Meet New Challenges. Wechsler, Jill // BioPharm International;Dec2011, Vol. 24 Issue 12, p12 

    The article focuses on the development in the medical products and reorganization of the administrative structure in the U.S. Food & Drug Administration (FDA). Stephen Spielberg, new deputy commissioner for medical products and tobacco, coordinates the activities related to medical devices,...

  • Critical Path Trickles Downstream To FDA Reviewers.  // Pharmaceutical Processing;Jan2008, Vol. 24 Issue 1, p38 

    The article discusses the U.S. Food and Drug Administration (FDA) reviewer's lack of interest to the Critical Path Initiative. Brian Harvey, a former director of FDA, states that reviewers follow established regulatory standards inspite exposure to new ideas and drug development in the Center...

  • Drug Safety -- Funding.  // Biomedical Market Newsletter;3/7/2011, p807 

    The article presents a speech by Janet Woodcock, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food & Drug Administration (FDA), before the U.S. Subcommittee on Agriculture, Rural Development, Food & Drug Administration, and Related Agencies House Committee on...

  • Drug Quality at Center Stage for FDA and Manufacturers. Wechsler, Jill // Pharmaceutical Technology;Jan2013, Vol. 37 Issue 1, p24 

    The article discusses the need of re-evaluation of the U.S. Food and Drug Administration (FDA's) drug regulatory policies related to modernization of biopharmaceutical production. It mentions that companies have fallen short of modernization to quality policy and improvement. It mentions the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics